Inventiva FIRST LOOK: Phase 2 (LEGEND) trial of lani combo in MASH and T2D hits
Inventiva reported positive topline data from the phase 2 (LEGEND) trial of lanifibranor + empagliflozin in MASH and T2D. In addition to hitting on the primary endpoint (HbA1c), we note the stabilisation of weight as well as improvements in secondary outcomes (e.g. liver enzymes and fibrosis markers). In our view, the results boost lanifibranor's positioning in MASH, demonstrating its potential as a combination therapy, which is important given that combinations will likely be required to address the disease co-morbidities. We reiterate our BUY rating and € 10 TP.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.